Issue Date: July 15, 2013
Small-Molecule Oncology Firm Debuts
Biotech company Array BioPharma and investment firm Aisling Capital have joined to form and fund Loxo Oncology to develop small-molecule drugs that treat cancer. Loxo’s first drug candidate is an Array-invented preclinical compound that targets an oncogenic activating mutation. The new firm will fund chemistry research at Array, which is eligible to receive up to $434 million in milestone payments. The partners say the collaboration between Loxo and Array is a solution to the biotech industry quandary of how to fund innovation without funding duplicative infrastructure.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society